首页IMGN • BMV
add
ImmunoGen Ord Shs
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2023年9月info | 年同比变化 |
|---|---|---|
收入 | 1.13亿 | 637.72% |
经营支出 | 3774.40万 | 12.26% |
净收入 | 3074.80万 | 139.54% |
净利润率 | 27.11 | 105.36% |
每股收益 | 0.10 | 132.26% |
息税折旧摊销前利润 | 2637.90万 | 134.26% |
有效税率 | -3.94% | — |
资产负债表
总资产
负债总额
| (USD) | 2023年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 6.06亿 | 95.64% |
总资产 | 8.22亿 | 129.13% |
负债总额 | 2.61亿 | 44.09% |
权益总额 | 5.62亿 | — |
发行在外的股份 | 2.66亿 | — |
市净率 | 127.25 | — |
资产回报率 | 8.45% | — |
资本回报率 | 10.17% | — |
现金流
现金净变动
| (USD) | 2023年9月info | 年同比变化 |
|---|---|---|
净收入 | 3074.80万 | 139.54% |
来自运营的现金 | 277.00万 | 104.31% |
投资现金 | -135.40万 | -124.92% |
融资现金 | 3213.20万 | 7,056.35% |
现金净变动 | 3354.80万 | 152.12% |
自由现金流 | -232.41万 | 91.72% |
简介
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
CEO
成立时间
1981
员工数量
277
